Old West Investment Management LLC Invests $22.47 Million in Illumina, Inc. $ILMN

Old West Investment Management LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, Holdings Channel reports. The fund purchased 127,804 shares of the life sciences company’s stock, valued at approximately $22,472,000. Illumina comprises approximately 2.4% of Old West Investment Management LLC’s holdings, making the stock its 5th biggest position.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter valued at approximately $25,000. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina in the 4th quarter worth $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter worth $26,000. Elevation Wealth Partners LLC increased its holdings in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares in the last quarter. Finally, Activest Wealth Management raised its stake in shares of Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Scott D. Ericksen sold 1,500 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock valued at $255,966,311 over the last three months. Insiders own 2.90% of the company’s stock.

Illumina Price Performance

NASDAQ ILMN opened at $190.89 on Monday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00. The firm has a market capitalization of $28.82 billion, a P/E ratio of 35.61, a PEG ratio of 2.69 and a beta of 1.44. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a 50-day moving average price of $183.78 and a 200-day moving average price of $150.54.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ILMN shares. JPMorgan Chase & Co. upped their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Canaccord Genuity Group boosted their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Royal Bank Of Canada upped their target price on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.